Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Non–Small Cell Lung Cancer Treated With First-Line Therapy
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.9655
Abstract: Key Points Question Is it feasible to assess solid tumor response to treatment from electronic health record (EHR) documentation and how does it correlate with clinical trial standards? Findings This cohort study found that a… read more here.
Keywords: imaging response; recist; clinician documented; response ... See more keywords
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04601-3
Abstract: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient (PPQ) and NETest are effective in… read more here.
Keywords: response; ppq; recist; non responders ... See more keywords
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.08.020
Abstract: OBJECTIVES To investigate the inter- and intra-reader agreement of immune Response Evaluation Criteria in Solid Tumors (iRECIST) and Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in patients with lung cancer treated with… read more here.
Keywords: inter; agreement; response; recist ... See more keywords
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0558-7
Abstract: BackgroundThe purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib.MethodA multicentre, prospective study was conducted in 10 Spanish centres. Computed… read more here.
Keywords: pancreatic neuroendocrine; study; recist; versus recist ... See more keywords
Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: FDG Uptake and Risk Stratification
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000002394
Abstract: Purpose This study investigated the prognostic role of tumor 18F-FDG uptake on pretreatment scans as an independent indicator and whether its addition improves risk prediction from Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST… read more here.
Keywords: fdg uptake; 18f fdg; recist; tumor ... See more keywords
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2019-000146
Abstract: Background Response criteria developed when cytotoxic chemotherapy was the predominant therapeutic modality to treat patients with cancer, do not capture the full spectrum of tumor response patterns observed with anti-PD-1/PD-L1 antibody treatment. iRECIST was developed… read more here.
Keywords: irecist; anti antibody; response; recist ... See more keywords
Imaging endpoints for clinical trial use: a RECIST perspective
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005092
Abstract: Twenty years after its initial introduction, Response Evaluation Criteria in Solid Tumors (RECIST) remains today a unique standardized tool allowing uniform objective evaluation of response in solid tumors in clinical trials across different treatment indications.… read more here.
Keywords: trial use; recist; clinical trial; imaging endpoints ... See more keywords
Active Surveillance in Patients with Extra-abdominal Desmoid-Type Fibromatosis: A Pooled Analysis of Three Prospective Observational Studies
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-24-2340
Abstract: Abstract Purpose: Three prospective observational studies (Italy, the Netherlands, and France) on active surveillance (AS) in patients with extra-abdominal desmoid-type fibromatosis support AS as a first-line approach. Identifying prognostic factors for the failure of AS… read more here.
Keywords: desmoid type; type; recist; regression ... See more keywords
Abstract 736: Deep learning response score using baseline and 12-week RECIST chest CTs enhances overall survival (OS) prediction in advanced NSCLC: external validation in a trial with dostarlimab
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-736
Abstract: Early response assessment and identification of patients (pts) with NSCLC likely to derive long-term benefit from immune checkpoint inhibitors (ICIs) are crucial for treatment planning and drug development. We developed a deep learning pipeline using… read more here.
Keywords: deep learning; response score; trial; response ... See more keywords
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT
Sign Up to like & getrecommendations! Published in 2024 at "Liver Cancer"
DOI: 10.1159/000537947
Abstract: Abstract Introduction: In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs. 12.3 months; HR 0.92, 95% CI 0.79–1.06). The objective response… read more here.
Keywords: response; per recist; tumor responses; recist ... See more keywords
Organ-agnostic automated RECIST measurements across time points with foundation models.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e13669
Abstract: e13669 Background: RECIST 1.1 remains the gold standard for evaluating tumor response in clinical trials and patient care. However, its reliance on manual measurements introduces subjectivity and inter-observer variability, which can affect the accuracy of… read more here.
Keywords: time; time points; recist measurements; recist ... See more keywords